Regulation of Inflammatory Genes in Psoriasis

RECRUITING

I'm interested ...!!

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.

Conditions:

🦠 Psoriasis 🦠 Inflammation

🗓️ Study Start (Actual) 22 April 2014

🗓️ Primary Completion (Estimated) 10 April 2025

✅ Study Completion (Estimated) 28 April 2027

👥 Enrollment (Estimated) 13

🔬 Study Type OBSERVATIONAL

📊 Phase N/A

Locations:

📍 Birmingham, Alabama, United States

📋 Eligibility Criteria

Description

Inclusion Criteria:

* Clinical diagnosis of psoriasis
* Must be age 19 or older.
* Must be Fitzpatrick skin type I, II, III, IV, V, VI.

Exclusion Criteria:

* Subjects who do not have photosensitive disease and are not on photosensitizing medications.
* Subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy).
* Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants.
* Subjects who are pregnant.

Ages Eligible for Study: 19 Years to 99 Years (ADULT, OLDER_ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 17 April 2017
First Submitted that Met QC Criteria 19 April 2017
First Posted 24 April 2017

Study Record Updates

Last Update Submitted that Met QC Criteria 26 March 2024
Last Update Posted 28 March 2024
Last Verified March 2024